Investment Thesis
Skye Bioscience exhibits severe financial distress with no revenue generation, cumulative losses of $12.5M, and negative operating cash flow of $8.6M annually, leaving approximately 11 months of cash runway at current burn rate. The company's deteriorating profitability (-93.2% EPS decline YoY), negative returns (ROE -138.8%, ROA -64.4%), and apparent failure to commercialize its pharmaceutical pipeline present fundamental business viability concerns that cannot be offset by its modest liquidity position.
Strengths
- Strong liquidity with 1.78x current ratio, providing short-term operational flexibility
- Minimal leverage with 0.01x debt-to-equity ratio, reducing bankruptcy risk from debt default
- Modest asset base of $19.4M provides some liquidation value cushion
Risks
- Zero or negligible revenue indicates failed commercialization or pre-revenue stage with no near-term monetization
- Annual operating cash burn of $8.6M against $8.1M cash reserves provides less than 12 months of runway at current burn rate
- Negative returns on capital (-138.8% ROE, -64.4% ROA) demonstrate complete destruction of shareholder value
- Deteriorating EPS (-93.2% YoY) indicates worsening operational performance with no recovery trajectory visible
- Pharmaceutical sector execution risk: clinical failure, regulatory rejection, or competitive displacement of pipeline
Key Metrics to Watch
- Operating cash burn rate and remaining cash runway (critical near-term survival metric)
- Revenue generation (any emergence of commercial revenue would dramatically alter thesis)
- Operating loss trend and path to cash flow breakeven
- Clinical trial results and regulatory milestones for pharmaceutical pipeline
Financial Metrics
Revenue
N/A
Net Income
-12.5M
EPS (Diluted)
$-0.32
Free Cash Flow
-8.6M
Total Assets
19.4M
Cash
8.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-138.8%
ROA
-64.4%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
1.78x
Quick Ratio
1.78x
Debt/Equity
0.01x
Debt/Assets
53.6%
Interest Coverage
N/A
Long-term Debt
45.6K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T10:20:03.549315 |
Data as of: 2026-03-31 |
Powered by Claude AI